Healthcare · Profile from Healthcare Research Companion
Viz.ai, Inc.
The San Francisco AI company that taught the industry to sell clinical AI as a care-coordination workflow rather than a detection score. Its stroke software received the FDA De Novo authorization that created the computer-aided triage category (2018) and the first Medicare New Technology Add-on Payment for AI (FY2021). It then spread across ~2,000 US hospitals and into cardiology, pulmonology and oncology, and built a second business selling patient-identification services to drug and device companies.
At a glance
- Founded
- 2016, San Francisco (with R&D in Tel Aviv, Israel)
- Founders
- Chris Mansi, MD (neurosurgeon, CEO) and David Golan, PhD (machine-learning researcher, CTO at founding), who met at Stanford; some databases list additional co-founders (verify)
- Headquarters
- San Francisco, California
- Ownership / structure
- Private, venture-backed: investors include Kleiner Perkins, GV, Greenoaks, Threshold Ventures, CRV, Innovation Endeavors, Scale Venture Partners, Insight Partners and Tiger Global; venture debt from CIBC Innovation Banking (2023, reported)
- Leadership (2026)
- Chris Mansi, co-founder and CEO; David Golan, co-founder (board member; verify current role)
- Segment and buyer
- Health IT / AI (imaging and care coordination). Buyers are hospitals and health systems (stroke, neurovascular, cardiovascular, pulmonary and oncology service lines) and life-sciences companies (pharma and medtech)
- Scale
- "Nearly 2,000" US hospitals covering 230m+ lives (late 2025 and 2026, company figures), up from 1,000+ in 2024; 12–13 FDA clearances (company releases); 13 life-sciences partnerships (late 2025)
- Capital raised / valuation
- ~$290m in equity and debt (sources range from ~$252m to ~$297m): Series A $21m (2018), Series B $50m (2019), Series C $71m (2021), Series D $100m at ~$1.2bn (April 2022), ~$40m debt (2023, reported); no priced round since 2022 disclosed
- Signature moves (incl. failures)
- Founding around the stroke-transfer problem (2016); FDA De Novo for Viz Contact (February 2018); Medtronic distribution (2019); first AI NTAP (FY2021); multi-condition platform (2020–22); unicorn Series D at the 2022 peak, then no new round; life-sciences model and Viz HCM with Bristol Myers Squibb (2023); cluster-randomised trial of Viz LVO (2023); agentic AI, Salesforce and claimed profitability (2025–26)
9 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2016
Founding Stroke Coordination
Founding
2018
FDA De Novo Contact
Regulatory clearance / launch
2019
Medtronic Distribution and Series B
Partnership / funding round
2020
First AI NTAP
Reimbursement
2021
Beyond Stroke Platform Expansion
Launch / funding round
2022
Series D Unicorn at the Peak
Funding round
2023
Cluster Randomized Trial Evidence
Clinical evidence
2023
Life Sciences Model and Viz HCM
Partnership / new business line
2025
Agentic Platform and Profitability
AI launch / strategy reset